Suppr超能文献

甲状腺激素替代治疗期间的纤连蛋白

Fibronectin during thyroid hormone replacement therapy.

作者信息

Watzke H, Schwarz H P, Weissel M

出版信息

Thromb Res. 1987 Apr 15;46(2):347-53. doi: 10.1016/0049-3848(87)90296-9.

Abstract

Hemostasis may be affected by thyroid function in various ways. We studied plasma concentration of Fibronectin in 13 untreated patients after total thyroidectomy due to thyroid carcinoma. Fibronectin levels were significantly decreased compared to an equal numbered group of healthy volunteers (p 0.0005). The same patients were studied again after an oral thyroid replacement of 200 micrograms L-thyroxine/d over at least six weeks. Fibronectin had increased significantly, compared to untreated patients and controls resp. Furthermore, a significant positive correlation was found between plasma concentrations of Fibronectin and total T4 (r = 0.92; y = 6.617 + 0.52x). In contrast Factor V activity was low in untreated patients but normal during high dose replacement therapy. No correlation was found between Factor V and thyroid hormone concentrations. We discuss the relation between fibronectin plasma levels and thyroid hormones.

摘要

止血功能可能会受到甲状腺功能的多种影响。我们研究了13例因甲状腺癌接受全甲状腺切除术后未经治疗的患者血浆中纤连蛋白的浓度。与同等数量的健康志愿者组相比,纤连蛋白水平显著降低(p<0.0005)。在至少六周内每天口服200微克左甲状腺素进行甲状腺替代治疗后,对相同的患者再次进行研究。与未经治疗的患者及对照组相比,纤连蛋白显著增加。此外,纤连蛋白血浆浓度与总T4之间存在显著正相关(r = 0.92;y = 6.617 + 0.52x)。相比之下,未经治疗的患者中因子V活性较低,但在高剂量替代治疗期间正常。未发现因子V与甲状腺激素浓度之间存在相关性。我们讨论了纤连蛋白血浆水平与甲状腺激素之间的关系。

相似文献

1
Fibronectin during thyroid hormone replacement therapy.甲状腺激素替代治疗期间的纤连蛋白
Thromb Res. 1987 Apr 15;46(2):347-53. doi: 10.1016/0049-3848(87)90296-9.
3
Plasma fibronectin and thyroid function.血浆纤连蛋白与甲状腺功能
J Clin Pathol. 1985 Jan;38(1):64-7. doi: 10.1136/jcp.38.1.64.

引用本文的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验